Rallybio Corporation
RLYB
$0.535
$0.0715.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 457.89% | -87.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 457.89% | -87.29% | |||
| Cost of Revenue | -22.48% | -10.38% | |||
| Gross Profit | 24.96% | 7.48% | |||
| SG&A Expenses | -2.44% | 3.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.15% | -5.81% | |||
| Operating Income | 16.70% | 3.80% | |||
| Income Before Tax | 14.53% | 3.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.53% | 3.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.53% | 3.68% | |||
| EBIT | 16.70% | 3.80% | |||
| EBITDA | 16.72% | 3.79% | |||
| EPS Basic | 14.76% | 3.81% | |||
| Normalized Basic EPS | 14.75% | 3.80% | |||
| EPS Diluted | 14.76% | 3.81% | |||
| Normalized Diluted EPS | 14.75% | 3.80% | |||
| Average Basic Shares Outstanding | 0.26% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||